Cargando…

Identification of P3H1 as a Predictive Prognostic Biomarker for Bladder Urothelial Carcinoma Based on the Cancer Genome Atlas Database

PURPOSE: The extracellular matrix in the tumor microenvironment are closely related to the development of tumors. This study’s primary aim is to study the association between prolyl 3-hydroxylase 1 (P3H1) which mainly expresses collagen in extracellular matrix and the progression and prognosis of bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuanfeng, Chen, Yang, Chen, Zhiming, Zhou, Xinye, Chen, Shaochuan, Lan, Kaijian, Wang, Zhiping, Zhang, Yonghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697085/
http://dx.doi.org/10.2147/PGPM.S437974
_version_ 1785154704349593600
author Zhang, Yuanfeng
Chen, Yang
Chen, Zhiming
Zhou, Xinye
Chen, Shaochuan
Lan, Kaijian
Wang, Zhiping
Zhang, Yonghai
author_facet Zhang, Yuanfeng
Chen, Yang
Chen, Zhiming
Zhou, Xinye
Chen, Shaochuan
Lan, Kaijian
Wang, Zhiping
Zhang, Yonghai
author_sort Zhang, Yuanfeng
collection PubMed
description PURPOSE: The extracellular matrix in the tumor microenvironment are closely related to the development of tumors. This study’s primary aim is to study the association between prolyl 3-hydroxylase 1 (P3H1) which mainly expresses collagen in extracellular matrix and the progression and prognosis of bladder cancer (BC). METHODS: The clinical and transcriptome data were acquired from the cancer genome atlas database. BLCAsubtyping is used to evaluate tissue subtypes of BC. The COX proportional hazards can be used to evaluate the survival process’s influencing factors. Immunohistochemistry was used to identify differences in the expression of P3H1 in cancer and paired adjacent tissues. GSEA was used to investigate the underlying biological processes. Finally, ssGSEA, TIMER and pRRophetic were used to study the relationship between P3H1 and immune cell infiltration and drug sensitivity. RESULTS: The expression of P3H1 was substantially higher in highly invasive BC samples than in low invasive BC. P3H1 was an independent predictor of overall survival (HR = 1.12, p = 0.03). P3H1 expression was significantly higher in tumor tissues than adjacent normal tissues in clinical tissue samples, and was significantly higher in highly stage cancer than low stage cancer samples. Samples with high P3H1 expression had a higher level of immune cell infiltration and immune function, as well as a significant correlation with macrophage and dendritic cell infiltration and TGF-beta, Th1 cells, and macrophage regulation (cor >0.3, p <0.05). P3H1 high expression samples were substantially more sensitive to docetaxel, cisplatin, vinblastine, camptothecin, paclitaxel, and other medicines than P3H1 low expression samples. DISCUSSION: P3H1 is a possible oncogene and an independent predictor of poor prognosis in BC; it also has enhanced sensitivity to docetaxel, cisplatin, vinblastine, camptothecin, paclitaxel, and other medications.
format Online
Article
Text
id pubmed-10697085
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-106970852023-12-06 Identification of P3H1 as a Predictive Prognostic Biomarker for Bladder Urothelial Carcinoma Based on the Cancer Genome Atlas Database Zhang, Yuanfeng Chen, Yang Chen, Zhiming Zhou, Xinye Chen, Shaochuan Lan, Kaijian Wang, Zhiping Zhang, Yonghai Pharmgenomics Pers Med Original Research PURPOSE: The extracellular matrix in the tumor microenvironment are closely related to the development of tumors. This study’s primary aim is to study the association between prolyl 3-hydroxylase 1 (P3H1) which mainly expresses collagen in extracellular matrix and the progression and prognosis of bladder cancer (BC). METHODS: The clinical and transcriptome data were acquired from the cancer genome atlas database. BLCAsubtyping is used to evaluate tissue subtypes of BC. The COX proportional hazards can be used to evaluate the survival process’s influencing factors. Immunohistochemistry was used to identify differences in the expression of P3H1 in cancer and paired adjacent tissues. GSEA was used to investigate the underlying biological processes. Finally, ssGSEA, TIMER and pRRophetic were used to study the relationship between P3H1 and immune cell infiltration and drug sensitivity. RESULTS: The expression of P3H1 was substantially higher in highly invasive BC samples than in low invasive BC. P3H1 was an independent predictor of overall survival (HR = 1.12, p = 0.03). P3H1 expression was significantly higher in tumor tissues than adjacent normal tissues in clinical tissue samples, and was significantly higher in highly stage cancer than low stage cancer samples. Samples with high P3H1 expression had a higher level of immune cell infiltration and immune function, as well as a significant correlation with macrophage and dendritic cell infiltration and TGF-beta, Th1 cells, and macrophage regulation (cor >0.3, p <0.05). P3H1 high expression samples were substantially more sensitive to docetaxel, cisplatin, vinblastine, camptothecin, paclitaxel, and other medicines than P3H1 low expression samples. DISCUSSION: P3H1 is a possible oncogene and an independent predictor of poor prognosis in BC; it also has enhanced sensitivity to docetaxel, cisplatin, vinblastine, camptothecin, paclitaxel, and other medications. Dove 2023-12-01 /pmc/articles/PMC10697085/ http://dx.doi.org/10.2147/PGPM.S437974 Text en © 2023 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhang, Yuanfeng
Chen, Yang
Chen, Zhiming
Zhou, Xinye
Chen, Shaochuan
Lan, Kaijian
Wang, Zhiping
Zhang, Yonghai
Identification of P3H1 as a Predictive Prognostic Biomarker for Bladder Urothelial Carcinoma Based on the Cancer Genome Atlas Database
title Identification of P3H1 as a Predictive Prognostic Biomarker for Bladder Urothelial Carcinoma Based on the Cancer Genome Atlas Database
title_full Identification of P3H1 as a Predictive Prognostic Biomarker for Bladder Urothelial Carcinoma Based on the Cancer Genome Atlas Database
title_fullStr Identification of P3H1 as a Predictive Prognostic Biomarker for Bladder Urothelial Carcinoma Based on the Cancer Genome Atlas Database
title_full_unstemmed Identification of P3H1 as a Predictive Prognostic Biomarker for Bladder Urothelial Carcinoma Based on the Cancer Genome Atlas Database
title_short Identification of P3H1 as a Predictive Prognostic Biomarker for Bladder Urothelial Carcinoma Based on the Cancer Genome Atlas Database
title_sort identification of p3h1 as a predictive prognostic biomarker for bladder urothelial carcinoma based on the cancer genome atlas database
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697085/
http://dx.doi.org/10.2147/PGPM.S437974
work_keys_str_mv AT zhangyuanfeng identificationofp3h1asapredictiveprognosticbiomarkerforbladderurothelialcarcinomabasedonthecancergenomeatlasdatabase
AT chenyang identificationofp3h1asapredictiveprognosticbiomarkerforbladderurothelialcarcinomabasedonthecancergenomeatlasdatabase
AT chenzhiming identificationofp3h1asapredictiveprognosticbiomarkerforbladderurothelialcarcinomabasedonthecancergenomeatlasdatabase
AT zhouxinye identificationofp3h1asapredictiveprognosticbiomarkerforbladderurothelialcarcinomabasedonthecancergenomeatlasdatabase
AT chenshaochuan identificationofp3h1asapredictiveprognosticbiomarkerforbladderurothelialcarcinomabasedonthecancergenomeatlasdatabase
AT lankaijian identificationofp3h1asapredictiveprognosticbiomarkerforbladderurothelialcarcinomabasedonthecancergenomeatlasdatabase
AT wangzhiping identificationofp3h1asapredictiveprognosticbiomarkerforbladderurothelialcarcinomabasedonthecancergenomeatlasdatabase
AT zhangyonghai identificationofp3h1asapredictiveprognosticbiomarkerforbladderurothelialcarcinomabasedonthecancergenomeatlasdatabase